Delisting of Securities of Tuscan Holdings Corp. II; Clovis Oncology, Inc.; ZyVersa Therapeutics, Inc.; Otonomy, Inc., and Forward Pharma A/S from The Nasdaq Stock Market

GlobeNewswire
2022/12/28

NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, unit, and warrant of Tuscan Holdings Corp. II. Tuscan Holdings Corp. II’s securities were suspended on November 21, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Clovis Oncology, Inc. Clovis Oncology, Inc.’s securities were suspended on December 21, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the warrants of ZyVersa Therapeutics, Inc. ZyVersa Therapeutics, Inc.’s warrants were suspended on December 21, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Otonomy, Inc. Otonomy, Inc.’s securities were suspended on December 23, 2022, and have not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the American Depositary Shares of Forward Pharma A/S. Forward Pharma A/S’s securities were suspended on December 28, 2022, and have not traded on Nasdaq since that time.

Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delistings. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delisting and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.

-NDAQO-


免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10